Elcon Drugs And Formulations Limited - Company Profile

It is a pharma public limited company based in Jaipur, Rajasthan, India, established in 1994.
1994 Jaipur, Rajasthan, India Active
Last Updated:
Access Report
About Elcon Drugs And Formulations Limited

Elcon Drugs And Formulations Limited, a active public limited company, was established on 04 January 1994 in Jaipur, Rajasthan, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U24232RJ1994PLC007922. Registered under ROC Roc Jaipur. it is unlisted. It has an authorized capital of ₹8.00 M and a paid-up capital of ₹7.72 M.

It upholds a compliant status. Employing 10 professional, Its leadership includes Amit Khandelwal (Whole-Time Director), Shiven Khandelwal (Whole-Time Director), Anuradha Khandelwal (Whole-Time Director). Past directors included Kailash Khandelwal, Amit Khandelwal, Naveen Khandelwal. It holds ₹4.47 M open charges and ₹5.85 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at G-2, G-3, G R Tower, Hathoj Mod, Bindayaka Road, Jaipur, Rajasthan, 302012.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24232RJ1994PLC007922

  • Registration Number

    007922

  • Incorporation Date

    04 January 1994

  • Authorized Capital

    ₹8.00 M

  • Paid-Up Capital

    ₹7.72 M

  • ROC Code

    Roc Jaipur

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 8.00 M
  • Paid Up Capital ₹ 7.72 M
  • Company Age 32 Year, 2 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 4.47 M
  • Satisfied Charges ₹ 5.85 Cr
  • Revenue Growth **** 623.06%
  • Profit Growth **** 672.72%
  • Ebitda **** 1020.24%
  • Net Worth 375.63%
  • Total Assets **** 1281.72%
Company report

Elcon Drugs And Formulations Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Elcon Drugs And Formulations Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Elcon Drugs And Formulations Limited?
Current Directors
Name Designation Appointment Date Status
Amit Khandelwal Whole-Time Director 04 Jan 1994 Current
Shiven Khandelwal Whole-Time Director 25 Jan 2020 Current
Anuradha Khandelwal Whole-Time Director 15 Jul 2015 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 22 Jul 2015 Past
Pramod Abcsdd Director 30 Sep 2015 Past
Pramod Abcsdd Director 16 Jul 2015 Past
Pramod Abcsdd Whole-Time Director 27 Jan 2020 Past
Pramod Abcsdd Additional Director 31 Dec 2020 Past
Pramod Abcsdd Additional Director 30 Sep 2015 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Elcon Drugs And Formulations.

Elcon Drugs And Formulations Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 623.06% increase. The company also saw a substantial improvement in profitability, with a 672.72% increase in profit. The company's net worth Soared by an impressive increase of 375.63%.

Elcon Drugs And Formulations revenue growth over time
Elcon Drugs And Formulations profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 623.06%
*******
*******
*******
*******
Revenue from Operations
*******
 742.54%
*******
*******
*******
*******
Total Assets
*******
 1281.72%
*******
*******
*******
*******
Profit or Loss
*******
 672.72%
*******
*******
*******
*******
Net Worth
*******
 375.63%
*******
*******
*******
*******
EBITDA
*******
 1020.24%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Elcon Drugs And Formulations?

In 2023, Elcon Drugs And Formulations had a promoter holding of 99.85% and a public holding of 0.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹4,469,150.00

Satisfied Charges

₹58,500,000.00

Charges Breakdown by Lending Institutions
  • State Bank Of India : 0.30 Cr
  • Hdfc Bank Limited : 0.15 Cr
Latest Charge Details
Date Lender Amount Status
05 Feb 2025 Hdfc Bank Limited ₹1.47 M Open
25 Jan 2001 State Bank Of India ₹3.00 M Open
30 Sep 2017 Others ₹2.25 Cr Satisfied
29 Feb 2016 Tata Capital Financial Services Limited ₹2.00 Cr Satisfied
15 Oct 2004 State Bank Of India ₹2.70 M Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Elcon Drugs And Formulations?

Elcon Drugs And Formulations has a workforce of 10 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Elcon Drugs And Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elcon Drugs And Formulations's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Elcon Drugs And Formulations
Recent Activity within the Organization
  • Annual General Meeting

    The activity Elcon Drugs And Formulations Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was completed.

  • Balance Sheet

    The activity Elcon Drugs And Formulations Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Jaipur. was completed.

  • Charges

    A charge with Hdfc Bank Limited amounted to Rs. 1.47 M with Charge ID 101077061 was registered on 05 Feb 2025. was recorded as a recent event.

  • Director Appointment

    Progress on Shiven Khandelwal was appointed as a Whole-time director was appointed as a Whole-time director on 25 Jan 2020 & has been associated with this company since 6 years 1 month . was documented.

  • Charges

    A charge registered on 30 Sep 2017 via Charge ID 100145759 with Others was fully satisfied on 13 Jan 2020. was recorded as a recent event.

  • Charges

    Progress on A charge registered on 29 Feb 2016 via Charge ID 10625274 with Tata Capital Financial Services Limited was fully satisfied on 08 Dec 2017. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Elcon Drugs And Formulations Limited?

The CIN of Elcon Drugs And Formulations Limited is U24232RJ1994PLC007922.

Where is Elcon Drugs And Formulations Limited headquartered?

Elcon Drugs And Formulations Limited is headquartered at G-2, G-3, G R Tower, Hathoj Mod, Bindayaka Road, Jaipur, Rajasthan, 302012.

When was Elcon Drugs And Formulations Limited incorporated?

Elcon Drugs And Formulations Limited was incorporated on 04 January 1994.

Who are the current directors of Elcon Drugs And Formulations Limited?

The current directors of Elcon Drugs And Formulations Limited are

What is the primary industry of Elcon Drugs And Formulations Limited?

The primary industry of Elcon Drugs And Formulations Limited is Trade.

Is Elcon Drugs And Formulations Limited a listed company?

Elcon Drugs And Formulations Limited is unlisted.

What is the capital structure of Elcon Drugs And Formulations Limited?

The authorized capital of Elcon Drugs And Formulations Limited is ₹8.00 M, and the paid-up capital is ₹7.72 M.

What is the compliance status of Elcon Drugs And Formulations Limited?

The compliance status of Elcon Drugs And Formulations Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available